In the Tamsulosin prostate hypertrophy treatment market worth ₩170 billion per year, Rx amount of generics increased by 10% compared to last year. During the same period, the original decreased by 10%, with generic accounting for more than 60% of the total market.

According to UBIST, a pharmaceutical market research institute on the 2nd, the market size of Tamsulosin for prostate hypertrophy in the first half of last year is ₩83.7 billion. Compared to ₩82.6 billion in the first half of last year, it increased by 1%.


Considering that prescriptions for prostate hypertrophy treatments are usually concentrated in the third and fourth quarters, it is expected to expand to